|
1
|
Dos Santos GA, Kats L and Pandolfi PP:
Synergy against PML-RARa: targeting transcription, proteolysis,
differentiation and self-renewal in acute promyelocytic leukemia. J
Exp Med. 210:2793–2802. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanz MA and Lo-Coco F: Modern approaches
to treating acute promyelocytic leukemia. J Clin Oncol. 29:495–503.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lallemand-Breitenbach V, Zhu J, Chen Z and
de Thé H: Curing APL through PML/RARA degradation by As2O3. Trends
Mol Med. 18:36–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adés L, Guerci A, Raffoux E, et al: Very
long-term outcome of acute promyelocytic leukemia after treatment
with all-trans retinoic acid and chemotherapy: The European APL
Group experience. Blood. 115:1690–1696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lo-Coco F, Avvisati G, Vignetti M, et al:
Retinoic acid and arsenic trioxide for acute promyelocytic
leukemia. New Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Montesinos P, Bergua JM, Vellenga E, et
al: Differentiation syndrome in patients with acute promyelocytic
leukemia treated with all-trans retinoic acid and anthracycline
chemotherapy: Characteristics, outcome and prognostic factors.
Blood. 113:775–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Lu C, Jiang M, et al: Traditional
chinese medicine-based network pharmacology could lead to new
multicompound drug discovery. Evid Based Complement Alternat Med.
2012:1497622012.PubMed/NCBI
|
|
8
|
Huang SL, Guo A, Xiang Y, et al: Clinical
study nf the treatment of acute promyelocytic leukemia mainly with
composite indigo naturalis tablets. Zhonghua Xue Ye Xue Za Zhi.
1:26–28. 1995.(In Chinese).
|
|
9
|
Xiang Y, Huang S, Guo A, et al: The
analysis of therapeutic efficiency on treating acute promyelocytic
leukemia (APL) with Compound Huangdai Tablets. Zhonghua Xue Ye Xue
Za Zhi. 13:11–12. 2000.(In Chinese).
|
|
10
|
Xiang Y, Huang S, Guo A, et al: The
influence on long-term survey of the patients with acute
promyelocytic leukemia treated alternatively with compound huang
dai tablets and chemotherapy. Zhonghua Xue Ye Xue Za Zhi. 16:11–12.
2003.(In Chinese).
|
|
11
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the
classification of the acute leukaemias. French-American-British
(FAB) co-operative group. Br J Haematol. 33:451–458. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rosenauer A, Raelson JV, Nervi C, Eydoux
P, DeBlasio A and Miller WH Jr: Alterations in expression, binding
to ligand and DNA and transcriptional activity of rearranged and
wild-type retinoid receptors in retinoid-resistant acute
promyelocytic leukemia cell lines. Blood. 88:2671–2682.
1996.PubMed/NCBI
|
|
13
|
Liu Y, He P, Zhang M, et al: Silencing of
the human SET gene in vitro with lentivirus-mediated RNA
interference. Mol Med Rep. 7:843–847. 2013.PubMed/NCBI
|
|
14
|
Roberts TF, Sprague K, Schenkein D, Miller
KB and Relias V: Hyperleukocytosis during induction therapy with
arsenic trioxide for relapsed acute promyelocytic leukemia
associated with central nervous system infarction. Blood.
96:4000–4001. 2000.PubMed/NCBI
|
|
15
|
Wu J, Shao Y, Liu J, Chen G and Ho PC: The
medicinal use of realgar (As4 S4) and its recent development as an
anticancer agent. J Ethnopharmacol. 135:595–602. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gong Y, Li Y, Lu Y, et al: Bioactive
tanshinones in Salvia miltiorrhiza inhibit the growth of prostate
cancer cells in vitro and in mice. Int J Cancer. 129:1042–1052.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Zhou GB, Liu P, et al: Dissection
of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis
as an effective treatment for promyelocytic leukemia. Proc Natl
Acad Sci USA. 105:4826–4831. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang HN, Pang JH, Yang SH, et al:
Inhibitory effect of indigo naturalis on tumor necrosis
factor-alpha-induced vascular cell adhesion molecule-1 expression
in human umbilical vein endothelial cells. Molecules. 15:6423–6435.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
The Coorperation Group of Phase II
Clinical Trial of Compound Huangdai Tablet, . Phase II clinical
trial of compound Huangdai tablet in newly diagnosed acute
promyelocytic leukemia. Chin J Hematol. 27:801–804. 2006.
|
|
20
|
Gong JX, Meng JB and Ma Y: Effects of
all-trans retinoic acid and compound huangdai tablet sequential
maintenance treatment on the long-term efficacy of acute
promyelocytic leukemia patients. Zhongguo Zhong Xi Yi Jie He Za
Zhi. 32:1473–1476. 2012.(In Chinese). PubMed/NCBI
|
|
21
|
Xiang Y, Chang XH and Cheng YB: Effect of
post-remission therapy mainly with compound huangdai tablet on
long-term survival of patients with acute promyelocytic leukemia.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 30:1253–1256. 2010.(In
Chinese). PubMed/NCBI
|
|
22
|
Sun GL: Treatment of acute promyelocytic
leukemia (APL) with all-trans retinoic acid (ATRA): A report of
five-year experience. Zhonghua Zhong Liu Za Zhi. 15:125–129.
1993.(In Chinese). PubMed/NCBI
|
|
23
|
Chen S, Fang Y, Ma L, Liu S and Li X:
Realgar-induced apoptosis and differentiation in all-trans retinoic
acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells. Int J
Oncol. 40:1089–1096. 2012.PubMed/NCBI
|
|
24
|
Chan E, Tan M, Xin J, Sudarsanam S and
Johnson DE: Interactions between traditional Chinese medicines and
Western therapeutics. Curr Opin Drug Discov Devel. 13:50–65.
2010.PubMed/NCBI
|
|
25
|
Tang D, Zhang Z, Gao Y, Wei Y and Han L:
Protective effects of serum containing Ginkgo biloba extract
on glomerulosclerosis in rat mesangial cells. J Ethnopharmacol.
124:26–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
